Structure of Deferoxamine Mesylate
CAS No.: 138-14-7
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Deferoxamine mesylate as a chelating agent used to remove excess iron from the body, treat acute iron poisoning, especially in small children, used to treat hemochromatosis, that can be either genetic or acquired. It has been previously reported to induce hypoxia and hypoxia-inducible factor-1α (HIF-1α) expression.
Synonyms: Desferrioxamine B mesylate; DFOM; DFX
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 138-14-7 |
Formula : | C26H52N6O11S |
M.W : | 656.79 |
SMILES Code : | O=C(N(CCCCCN)O)CCC(NCCCCCN(O)C(CCC(NCCCCCN(O)C(C)=O)=O)=O)=O.CS(=O)(O)=O |
Synonyms : |
Desferrioxamine B mesylate; DFOM; DFX
|
MDL No. : | MFCD00058605 |
InChI Key : | IDDIJAWJANBQLJ-UHFFFAOYSA-N |
Pubchem ID : | 62881 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P280-P305+P351+P338 |
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
HepG2 cells | 100 μM | 48 hours | To evaluate the effect of HIF1α activation on Cyp1a1 and Cyp1a2 expression. Results showed that DFO treatment increased the expression of HIF1α target genes while decreasing the expression of Cyp1a1 and Cyp1a2. | PMC10235873 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT00004982 | Iron Overload ... More >> Thalassemia Less << | Phase 1 | Completed | - | United States, New York ... More >> Cornell University Medical College New York, New York, United States, 10021 Less << |
NCT00447694 | Beta-thalassemia ... More >> Iron Overload Less << | Phase 2 | Completed | - | United States, California ... More >> Childrens Hospital of Los Angeles Los Angeles, California, United States, 90027 Children's Hospital and Research Center at Oakland Oakland, California, United States, 94609 United States, Illinois Children's Memorial Hospital Chicago, Illinois, United States, 60614 Less << |
NCT00110266 | Myelodysplastic Syndrome ... More >> Iron Overload Less << | Phase 2 | Completed | - | - |
NCT00001203 | - | Completed | - | United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less << | |
NCT02065492 | Thalassemia | Phase 2 Phase 3 | Completed | - | Pakistan ... More >> Aga Khan University Hospital Karachi, Sindh, Pakistan, 74800 Less << |
NCT00293098 | - | - | - | United States, Pennsylvania ... More >> The Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 Less << | |
NCT00000595 | Anemia (Iron-Loading) ... More >> Beta-Thalassemia Hematologic Diseases Hemoglobinopathies Thalassemia Iron Overload Hemochromatosis Less << | Phase 2 | Completed | - | - |
NCT01905774 | - | Completed | - | Israel ... More >> Ha'Emek Medical Center Afula, Israel, 18101 Less << | |
NCT00749515 | Transfusion-dependent Hemachro... More >>matosis Thalassemia Major Sickle Cell Disease Less << | Phase 4 | Completed | - | United States, Massachusetts ... More >> Children's Hospital Boston Boston, Massachusetts, United States, 02115 Less << |
NCT01996683 | Beta-thalassemia ... More >> Serum Ferritin Iron Chelation Therapy Less << | Not Applicable | Unknown | November 2015 | Egypt ... More >> Pediatric Hematology clinic, Ain Shams University Not yet recruiting Cairo, Egypt Principal Investigator: Mohsen S Elalfy, professor Sub-Investigator: Amira A Adly, Assist. prof. Sub-Investigator: Yasmine I Elhenawy, lecturer Less << |
NCT01956799 | - | Active, not recruiting | December 2018 | Italy ... More >> Ematologia, AO SS. Antonio e Biagio Alessandria, AL, Italy, 15121 Clinica di Ematologia, AOU Ospedale di Torrette Ancona, AN, Italy, 60020 Ematologia con trapianto, AOU Policlinico di Bari Bari, BA, Italy, 70124 Istituto di Ematologia e Oncologia Medica, Policlinico S.Orsola Bologna, BO, Italy, 40138 Ematologia, Spedali Civili Brescia, BS, Italy, 25123 Struttura complessa di Ematologia, ASO S.Croce e Carle Cuneo, CN, Italy, 12100 Cattedra di Ematologia Policlino Careggi Firenze, FI, Italy, 50134 Clinica Ematologica, Università di Genova Genova, GE, Italy, 16132 U.O. Clinica Medicina Interna, IRCCS San Martino IST Genova, GE, Italy, 16132 UO Ematologia e CTMO, Ospedale Civile G. da Saliceto Piacenza, PC, Italy, 29121 Ematologia, Università di Padova Padova, PD, Italy, 35128 Struttura Cattedra di Ematologia e CTMO, AOU di Parma Parma, PR, Italy, 43100 Ematologia e Centro Trapianti, Centro di Riferimento Oncologico della Basilicata Rionero in Vulture, PZ, Italy, 85028 Medicina Interna II Divisione di Ematologia, Ospedale S. Luigi Gonzaga Orbassano, TO, Italy, 10043 Ematologia 2, AOU Città della Salute e della Scienza Torino, TO, Italy, 10126 S.C.D.U. Ematologia e Terapie cellulari, Ospedale Mauriziano Torino, TO, Italy, 10128 UOC Ematologia, Ospedale S.Eugenio Roma, Italy, 00144 Policlinico A.Gemelli Roma, Italy, 00168 UOC Ematologia, AO S. Giovanni Addolorata Roma, Italy, 00184 Ematologia, AO S. Andrea Roma, Italy, 00189 Less << | |
NCT02875262 | Intracranial Aneurysm ... More >> Subarachnoid Hemorrhage Less << | Phase 1 Phase 2 | Not yet recruiting | June 1, 2018 | Netherlands ... More >> Radboudumc Not yet recruiting Nijmegen, Gelderland, Netherlands, 6500 HB Contact: Jeroen Boogaarts, M.D., Ph.D. 0031243615085 jeroen.boogaarts@radboudumc.nl Contact: Joost de Vries, M.D., Ph.D. 0031243615085 joost.devries@radboudumc.nl University Medical Center Groningen Not yet recruiting Groningen, Netherlands, 9713 GZ Contact: Marc van Dijk, M.D., Ph.,D. 00310503616161 j.m.c.van.dijk@umcg.nl Contact: Rob Groen, M.D., Ph.,D. 00310503616161 r.j.m.groen@umcg.nl Less << |
NCT00105495 | Thalassemia Major ... More >> Hemosiderosis Less << | Phase 4 | Completed | - | Greece ... More >> 1st Department of Pediatrics, Athens University, Aghia Sophia Children's Hospital Athens, Greece, 11527 Aghia Sophia Children's Hospital Athens, Greece, 11527 Italy Ospedale Regionale Microcitemie, Dipartimento di Scienze Cagliari, Sardegna, Italy, 09100 Dipartimento di Scienze e Dell' Adolescenza, University of Turin Turin, Italy, 10126 Less << |
NCT03137966 | Diabetic Foot Ulcer | Phase 2 | Not yet recruiting | December 31, 2022 | - |
NCT00658411 | Acute Myeloid Leukemia ... More >> Acute Lymphoblastic Leukemia Myelodysplastic Syndrome Less << | Not Applicable | Terminated(Closed due to slow ... More >>patient accrual) Less << | - | United States, Massachusetts ... More >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less << |
NCT00658411 | - | Terminated(Closed due to slow ... More >>patient accrual) Less << | - | - | |
NCT00738413 | Thalassemia | Phase 1 Phase 2 | Unknown | December 2009 | United States, New York ... More >> Weill Cornell Medical Center Recruiting New York, New York, United States, 10021 Contact: Robert W Grady, Ph.D. 212-746-3422 rwgrady@med.cornell.edu Contact: Kristen Muirhead, BS 212-746-3264 krm2066@med.cornell.edu Principal Investigator: Robert W Grady, Ph.D. Sub-Investigator: Patricia J Giardina, M.D. Less << |
NCT01511848 | Beta-thalassemia Major ... More >> Sickle Cell Disease Iron Hemosiderosis Less << | Phase 2 Phase 3 | Unknown | February 2013 | Egypt ... More >> Pediatric Hematology clinic, Ain Shams University Not yet recruiting Cairo, Egypt Less << |
NCT01752153 | Immune Abnormalities | Phase 1 | Completed | - | Iran, Islamic Republic of ... More >> Department of Immunology, School of Medicine, Shiraz University of Medical Sciences Shiraz, Fars, Iran, Islamic Republic of Less << |
NCT00999349 | Beta-thalassemia Major ... More >> Iron Overload Less << | Phase 2 Phase 3 | Unknown | - | Iran, Islamic Republic of ... More >> Isfahan University of Medical Sciences Isfahan, Iran, Islamic Republic of, 81744-176 Less << |
NCT02216513 | Subarachnoid Hemorrhage | Early Phase 1 | Terminated(Principle Investiga... More >>tor is moving to another institution and plans to restart this proctocol in the new location.) Less << | - | United States, Massachusetts ... More >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Less << |
NCT02367248 | Intracerebral Hemorrhage | Phase 1 Phase 2 | Unknown | December 2016 | China ... More >> Department of Neurology,Beijing Shijitan Hospital,Capital Medical University Recruiting Beijing, China, 100038 Contact: Maolin He, MD 0086-010-63926550 maolinh@sina.com Less << |
NCT01365104 | Stroke Proble... More >>m of Aging Less << | Early Phase 1 | Completed | - | United States, Massachusetts ... More >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Less << |
NCT01662895 | Intracerebral Hemorrhage | Phase 2 | Suspended(By DSMB due to incre... More >>ased incidence of ARDS. See modified protocol [NCT02175225) Less << | December 2018 | - |
NCT00598572 | Intracerebral Hemorrhage | Phase 1 | Completed | - | United States, Massachusetts ... More >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Less << |
NCT00901199 | Thalassemia I... More >>ron Overload Less << | Phase 4 | Completed | - | United States, California ... More >> CHRCO Oakland, California, United States, 94609 Less << |
NCT00349453 | Hemochromatosis | Phase 2 | Completed | - | Switzerland ... More >> Cantonal Hospital, Children's Clinic Aarau, Aargau, Switzerland, 5001 Cantonal Hospital Aarau, Aargau, Switzerland, 5001 Cantonal Hospital Graubünden Chur, Graubünden, Switzerland, 7000 Private practice Arzo, Ticino, Switzerland, 6864 Private practice Lugano, Ticino, Switzerland, 6900 Regional Hospital Lugano, Ticino, Switzerland, 6900 Private practice Riva San Vitale, Ticino, Switzerland, 6826 Private children's practice Brig, Wallis, Switzerland, 3900 Private practice Oerlikon, Zurich, Switzerland, 8050 Private children's practice Bern, Switzerland, 3014 Children's Hospital of Eastern Switzerland St. Gallen, Switzerland, 9006 University Children's Hospital Zurich, Switzerland, 8032 University Hospital Zurich, Switzerland, 8091 Less << |
NCT00350662 | Hemochromatosis | Phase 3 | Completed | - | Egypt ... More >> Pediatric Hospital, Cairo University Cairo, Egypt Turkey EGE University Medical School Bornova, Izmir, Izmir, Turkey, 35100 Less << |
NCT01369719 | Thalassemia I... More >>ron Overload Transfusion Related Complications Less << | Not Applicable | Completed | - | Iran, Islamic Republic of ... More >> Hormozgan University of Medical Sciences (HUMS) Bandar abbas, Hormozgan, Iran, Islamic Republic of, 79145-3388 Less << |
NCT02175225 | Intracerebral Hemorrhage | Phase 2 | Active, not recruiting | December 31, 2018 | - |
NCT03085771 | Diabetes Mellitus, Type 1 | Phase 2 | Recruiting | December 12, 2022 | Sweden ... More >> Karolinska University Hospital Recruiting Stockholm, Sweden, 17176 Contact: Sergiu Catrina, ass prof MD +46-8-51770000 sergiu-bogdan.Catrina@ki.se Contact: Neda Ekberg, PhD, MD +46-(0)8 51775449 Neda.Ekberg@ki.se Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.52mL 0.30mL 0.15mL |
7.61mL 1.52mL 0.76mL |
15.23mL 3.05mL 1.52mL |
Tags: Deferoxamine Mesylate | Desferrioxamine B mesylate | Hydroxylamines | Amines | Aliphatic Chain Hydrocarbons | Amides | Inorganic Salts | Apoptosis Inducer | HIF | Akt | ROS | Autophagy | Ras | Apoptosis | Tumor Metabolism | GPCR/G Protein | Angiogenesis | PI3K/AKT/mTOR | Cell Apoptosis/Death Detection | Immunology/Inflammation | Parkinson'S Disease and Alzheimer'S Disease | Apoptosis | PPAR Signaling Pathway | Epigenetics | Organic Building Blocks | Tumor Growth, Proliferation and Apoptosis | Synthetic Reagents | Autophagy | Tumor Epigenetics and Gene Regulation | Exosome | Endoplasmic Reticulum Stress | 138-14-7
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL